SCHEMBL274850

SCHEMBL274850

O=C(O)COc1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.68
ALDH1A1 P00352 2/20 0.62
FFAR1 O14842 2/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
CYP19A1 P11511 1/20 0.59
ESR1 P03372 1/20 0.59
PTPN7 P35236 2/20 0.58
MEN1 O00255 1/20 0.58
MAPT P10636 1/20 0.58
KMT2A Q03164 1/20 0.58
PTPN12 Q05209 1/20 0.58
THRA P10827 1/20 0.56
THRB P10828 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4820127 0.94 ALOX15 (0.61) ALOX15ALDH1A1FFAR1SMN1; SMN2CYP19A1
Formaldehyde SCHEMBL30592324 0.94 ALOX15 (0.61) ALOX15ALDH1A1FFAR1SMN1; SMN2CYP19A1
Chloroacetic Acid SCHEMBL7821121 0.92 ALOX15 (0.59) ALOX15ALDH1A1FFAR1SMN1; SMN2CYP19A1
SCHEMBL339492 0.91 ALOX15 (0.81) ALOX15ALDH1A1FFAR1SMN1; SMN2PTPN7
SCHEMBL1550206 0.90 FFAR1 (0.77) ALOX15ALDH1A1FFAR1SMN1; SMN2CYP19A1
SCHEMBL11261731 0.90 ESR1 (0.60) ALOX15ALDH1A1FFAR1SMN1; SMN2CYP19A1
SCHEMBL13616217 0.89 PPARD (0.67) ALOX15ALDH1A1FFAR1SMN1; SMN2CYP19A1
SCHEMBL9544330 0.89 ALOX15 (0.55) ALOX15ALDH1A1FFAR1SMN1; SMN2CYP19A1
SCHEMBL31742271 0.89 ALOX15 (0.55) ALOX15ALDH1A1FFAR1SMN1; SMN2CYP19A1
SCHEMBL6001984 0.87 ALDH1A1 (0.86) ALOX15ALDH1A1SMN1; SMN2CYP19A1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 553 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118531038-A Engineering strain transformation method for high-yield penicillin V and reduction of 4-hydroxy penicillin V impurities, engineering bacteria and application 浙江工业大学 2024-08-23 CN claimed
CN-117757009-A Preparation method of high-temperature-resistant high-efficiency sulfonated phenolic resin 荆州市学成实业有限公司 2024-03-26 CN claimed
EP-2992041-B1 METHODS FOR TREATING LIGNOCELLULOSIC MATERIALS VIRDIA INC (US) 2020-01-08 EP claimed
EP-2991998-B1 METHODS FOR PREPARING THERMALLY STABLE LIGNIN FRACTIONS VIRDIA INC (US) 2019-08-14 EP claimed
US-10138332-B2 Methods for treating lignocellulosic materials VIRDIA, INC. (US) 2018-11-27 US claimed
US-20170313826-A1 METHODS FOR TREATING LIGNOCELLULOSIC MATERIALS STORA ENSO OYJ (FI) 2017-11-02 US claimed
US-9683005-B2 Methods for preparing thermally stable lignin fractions VIRDIA, INC. (US) 2017-06-20 US claimed
US-9657146-B2 Methods for treating lignocellulosic materials VIRDIA, INC. (US) 2017-05-23 US claimed
US-20160130408-A1 METHODS FOR TREATING LIGNOCELLULOSIC MATERIALS STORA ENSO OYJ (FI) 2016-05-12 US claimed
US-20160102113-A1 METHODS FOR PREPARING THERMALLY STABLE LIGNIN FRACTIONS VIRDIA, INC. (US) 2016-04-14 US claimed
WO-1995034675-A1 IMPROVED ACYLATION METHOD FOR PENICILLINS AND CEPHALOSPORINS GIST-BROCADES B.V. (NL) 1995-12-21 WO claimed
EP-0374184-B1 CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES BAYLOR COLLEGE MEDICINE (US) 1994-01-12 EP claimed
US-5216024-A Compounds such as methyl p-hydroxypenyllactate, derivatives BAYLOR COLLEGE OF MEDICINE (US) 1993-06-01 US claimed
EP-0374184-A1 CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES. BAYLOR COLLEGE MEDICINE (US) 1990-06-27 EP claimed
WO-1989000849-A1 CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES BAYLOR COLLEGE OF MEDICINE (US) 1989-02-09 WO claimed
US-4470980-A Method of increasing oral absorption of β-lactam antibiotics INTERX RESEARCH CORP. (US) 1984-09-11 US claimed
EP-0036534-A1 An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-30 EP claimed
EP-0036145-A1 An orally administered drug form comprising a polar bioactive agent and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-23 EP claimed
EP-0035770-A2 An orally administered drug form comprising a glycosidic antibiotic and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-16 EP claimed
EP-0031561-A2 A rectally administered suppository comprising a drug and an adjuvant MERCK & CO. INC. (US) 1981-07-08 EP claimed